Analysis of serum vancomycin concentration after administration of different doses in children with Staphylococcus aureus pneumonia

ZHANG Guang-Li; ZHAMG Hui; LIU Ru; ZHANG Si-Ying; LI Jun-Qi; LI Ying; ZHANG Dong-Wei; LUO Zheng-Xiu

doi:10.7499/j.issn.1008-8830.2014.10.005

PDF(1143 KB)

Chinese Journal of Contemporary Pediatrics ›› 2014, Vol. 16 ›› Issue (10) : 984-987. DOI: 10.7499/j.issn.1008-8830.2014.10.005

TOPIC OF WORLD PNEUMONIA DAY

Analysis of serum vancomycin concentration after administration of different doses in children with Staphylococcus aureus pneumonia

ZHANG Guang-Li, ZHAMG Hui, LIU Ru, ZHANG Si-Ying, LI Jun-Qi, LI Ying, ZHANG Dong-Wei, LUO Zheng-Xiu

Author information +

History +

Abstract

Objective To analyze serum vancomycin concentration after administration of different therapeutic doses in children with Staphylococcus aureus pneumonia (SAP) in order to determine the appropriate dose of vancomycin in clinical administration. Methods The clinical data of 35 children who were diagnosed with SAP and treated with vancomycin from January 2008 to December 2013 were retrospectively analyzed. Results Among the 35 SAP cases with vancomycin therapy, 22 cases (63%) had serum vancomycin trough concentration monitored. The numbers of cases with vancomycin at 10, 12.5, and 15 mg/(kg·dose) × every 6 hours (q6h) were 11, 4 and 7, respectively. The mean serum trough concentration of vancomycin in the 15 mg/(kg·dose) group was 14.98 mg/L, which was significantly higher than in the 10 mg/(kg·dose) and 12.5 mg/(kg·dose) groups (4.97 and 8.00 mg/L respectively; P<0.05). The percentage of cases that reached the expected trough concentration in the 15 mg/(kg·dose) group (71%) was significantly higher than that in the 10 mg/(kg·dose) group (9%), but there was no significant difference in this percentage between the 15 mg/(kg·dose) and 12.5 mg/(kg·dose) groups (71% vs 25%). Conclusions The reasonable dosage of vancomycin for the treatment of pediatric SAP is 15 mg/(kg·dose) × q6h or 60 mg/(kg·d).

Key words

Vancomycin / Pneumonia / Staphylococcus aureus / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHANG Guang-Li, ZHAMG Hui, LIU Ru, ZHANG Si-Ying, LI Jun-Qi, LI Ying, ZHANG Dong-Wei, LUO Zheng-Xiu. Analysis of serum vancomycin concentration after administration of different doses in children with Staphylococcus aureus pneumonia[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(10): 984-987 https://doi.org/10.7499/j.issn.1008-8830.2014.10.005

References

[1] 李家泰. 临床药理学 [M]. 第3 版. 北京：人民卫生出版社,2007: 1024-1027.
[2] Liu C, Bayer A, Cosgrove SE, et a1. Clinical practice guidelinesby the infectious diseases society of America for the treatmentof methicillin-resistant Staphylococcus aureus infections inadultsand children[J]. Clin Infect Dis, 2011, 52(3): 285-292.
[3] 万古霉素临床应用中国专家共识（2011 版）[J]. 中国新药与临床杂志, 2011, 30(8): 561-573.
[4] 张海霞, 杨智, 何莉梅, 等. 235 例儿童万古霉素血药浓度与不良反应分 [J]. 实用药物与临床, 2013, 16(12): 1200-1203.
[5] 彭敏, 邓楠, 韦鸿雁, 等. 某院儿童住院患者万古霉素血药浓度监测及临床应用分析 [J]. 中国抗生素杂志, 2013, 38(10):795-798.
[6] 李秀娟. 万古霉素血药浓度对儿科临床疗效的研究 [J]. 临床合理用药杂志, 2013, 6(33): 39-43.
[7] 王丹, 刘春峰. 重症感染患儿万古霉素血药浓度分布特点分析 [J]. 中国实用儿科杂志, 2013, 28(11): 851-853.
[8] Avent ML, Vaska VL, Rogers BA, et al. Vancomycintherapeutics and monitoring: a contemporary approach[J]. InternMed J, 2013, 43(2): 110-119.
[9] Sanchez JZ, Dominguez AR, Lane JR, et al. Populationpharmacokinetics of vancomycin in adult and geriatric patients:comparison of eleven approaches[J]. Int J Clin Pharmacol Ther,2010, 48(8): 525-533.
[10] Pea F, Bertolissi M, Di Silvestre A, et al. TDM coupled withBayesian forecasting should be considered an invaluable tool foroptimizing vancomycin daily exposure in unstable critically illpatients [J]. Int J Antimicrob Agents, 2002, 20(5): 326-332.
[11] Nunn MO, Corallo CE, Aubron C, et al. Vancomycin dosing:assessment of time to therapeutic concentration and predictiveaccuracy of phmrmacokinetic modeling software[J]. AnnPharmacother, 2011, 45(6): 757-763.
[12] Hiraki Y, Onga T, Mizoguchi A, et al. Investigation of theprediction accuracy of vancomycin concentrations determinedby patient-specific parameters as estimated by Bayesiananalysis[J]. J Clin Pharm Ther, 2010, 35(5): 527-532.
[13] 叶志康, 李晓光, 翟所迪. 中国万古霉素治疗药物监测现况研究 [J]. 中国临床药理杂志, 2013, 29(7): 545-548.
[14] Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortalityfor methicillin-resistant Staphylococcus aureus health-careassociatedpneumonia: specific evaluation of vancomycinpharmacokinetic indices[J]. Chest, 2006, 130(4): 947-955.
[15] Ragab AR, Al-Mazroua MK, Al-Harony MA, et al. Incidenceand predisposing factors of vancomycin-induced nephrotoxicityin children[J]. Infect Dis Ther, 2013, 2(1): 37-46.
[16] McKamy S, Hernandez E, Jahng M, et al. Incidence andrisk factors influencing the development of vancomycinnephrotoxicity in children[J]. J Pediatr, 2011, 158(3): 422-426.
[17] Chen Y, Yang XY, Zeckel M, et al. Risk of hepatic events inpatients with vancomycin in clinical studies: a systematic reviewand meta-analysis[J]. Drug Saf, 2011, 34(1): 73-82.